Date & Time
06/20/2020 - 06/21/2020
10:00 am - 5:30 pm
Elizabeth Nielson an Ingmar Gorman
This 2-day training is designed for clinicians and healthcare providers who want to learn more about current psychedelic research and clinical practice, including how to work with patients who have a history of psychedelic use or have expressed an interest in using psychedelics.
Day 1 of this training will give you an overview of psychedelic drugs, and the current research with MDMA and psilocybin-assisted therapy. We will review recent and current clinical trials, outcomes, legal status, and what it all means for the future of addiction and trauma treatment.
We will also cover:
Historical justifications for psychedelic clinical research
Key theoretical approaches to psychedelic-assisted therapy
The state of psychedelic clinical research and rescheduling efforts
How psychedelic-assisted psychotherapy works with clients
We will also compare psychedelic integration psychotherapy both peer and shamanic settings.
Day 2 of this training introduces skills for psychedelic harm reduction and integration work in clinical settings, focusing on how to translate research findings into clinical practice.
•Discuss assessment and integration techniques, resources, and legal and ethical issues
•Learn to assess clients for key “red flags,” indicating psychiatric care is needed after a psychedelic experience
•Utilize principles of psychedelic-assisted therapy in initial assessments of clients who report psychedelic use
•Explore contraindications and discuss high-risk clients who are contemplating psychedelic use
•Describe the therapist’s role in a client’s integration psychotherapy process
Note: Limited enrollment. Recommended for licensed mental health care providers with an existing understanding of psychedelic-assisted therapy and psychedelic integration as well as health care providers. Continuing Education Credits available for psychologists and social workers. Please visit this website for Continuing Education Credits and pay directly.
Note: Clinicians and/or holistic health practitioners will be able to use the harm reduction and integration teachings of the workshops in their practices provided they are licensed practitioners in their field of work and do so in a way that’s consistent with their scope of practice.
A Two-Day Training
Saturday – Sunday, June 20 – June 21, 2020, 10:00 am – 5:30 pm
Members $410/ Nonmembers $450
Click here to read Therapists Are Unprepared to Talk to People About Taking Psychedelics.
Click here to read Ten Reasons Psychotherapists Should Learn About Psychedelics.
Related Program: Mindfulness & Psychedelics
New York Open Center
Ingmar Gorman, PhD, cofounder of Fluence, a psychedelic education project, is a psychologist who focuses on assisting populations who have had experiences with psychedelics. He is the site co-principal investigator and therapist on a Phase 3 clinical trial studying MDMA-assisted psychotherapy for post-traumatic stress disorder. Dr. Gorman is a board member of Horizons Media, Inc., a not for-profit and is organizer of the Horizons Conference: Perspectives on Psychedelics. After completing his NIH postdoctoral fellowship at NYU, Dr. Gorman now focuses his efforts on Fluence and the training of future therapists.